Libtayo (cemiplimab-rwlc)

Adult Dosing .

Dosage forms:  INJ

Special Note

[formulation clarification]

Info: nonproprietary name = cemiplimab-rwlc

[uses, dosing may vary]

Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments

cutaneous squamous cell CA, locally advanced or metastatic

[350 mg IV q3wk]

Info: for pts not eligible for curative surgery or XRT; give up to 24mo

basal cell CA, locally advanced or metastatic

[350 mg IV q3wk]

Info: for pts who have received a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate; give up to 24mo

locally advanced or metastatic non-small cell lung CA, first-line tx

[combo tx]

Dose: 350 mg IV q3wk; Info: for pts w/ no EGFR, ALK, or ROS1 genomic tumor aberrations not eligible for curative surgery or XRT

[monotherapy]

Dose: 350 mg IV q3wk; Info: for pts w/ high PD-L1-expressing tumor w/ no EGFR, ALK, or ROS1 genomic tumor aberrations not eligible for curative surgery or XRT

renal dosing

[see below]

CrCl >21: no adjustment; CrCl <21: not defined

HD/PD: not defined

hepatic dosing

[see below]

bilirubin 1.1-3x ULN: no adjustment; bilirubin >3x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.